Evaxion Biotech (NSADAQ:EVAX) has announced the completion of dosing for 16 patients in a Phase 2 trial of its lead asset, EVX-01, a personalized cancer vaccine under development for advanced melanoma.
According to Evaxion, the trial evaluates EVX-01 in combination with Merk’s anti-PD-1 therapy, KEYTRUDA. Each patient enrolled in the trial has received a unique vaccine designed and developed based on their individual biology. The trial remains on track for completion, with data readout expected in the second half of 2025.
“We are happy to report completion of the dosing in this important trial, demonstrating our strong capabilities in trial execution. Now we focus on carrying the trial through to completion and we are eagerly anticipating the full clinical data readout later this year. Based on the impressive data generated so far, we see that EVX-01 could potentially become a new and effective treatment option for advanced melanoma. With more than 300,000 new melanoma cases each year and significant medical needs, this offers great commercial potential for Evaxion,” Christian Kanstrup, CEO of Evaxion commented.
